Skip to main
  1. Stocks
  2. Benitec Biopharma Limited Sponsored ADR
  3. Forecast
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma is positioned attractively because BB-301 is targeting OPMD, a rare disease with no approved disease-modifying therapy and only limited symptomatic options, giving the program a clear unmet-need advantage. The company’s Ph1b/2a data and ESGCT updates showed robust, durable swallowing-function improvements and a 100% responder rate, while FDA discussions in 1Q27 support a pivotal Phase 3 design that management expects to finalize for a mid-2027 start. Financially, Benitec ended September with about $176M in cash, which should fund execution through major regulatory milestones and support its “silence-and-replace” strategy.

Bears say

Benitec Biopharma is viewed negatively because its operating expenses and cash burn have been greater than expected, signaling a business model that is still heavily dependent on external funding rather than self-sustaining operations. As a clinical-stage biotechnology company focused on developing BB-301 for OPMD, it has yet to demonstrate commercial revenue, leaving the investment case tied to uncertain clinical progress and the long duration typical of genetic medicine development. The need for equity issuances more frequently or at less attractive valuations than projected raises dilution risk for shareholders and suggests that financial discipline may remain strained as development costs continue to outpace available resources.

BNTC has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

BNTC Analyst Forecast & Price Prediction

Get the latest BNTC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BNTC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 5 analysts, BNTC has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


BNTC Analyst Forecast & Price Prediction

Get the latest BNTC stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BNTC

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BNTC stock data and trends